{"symbol":"BMY","fiscalQuarter":"Q4-2018","reportDate":"2019-01-24","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2018","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 1.88%","keyNumbers":[{"metric":"EPS","actual":"$0.94","expected":"N/A","surprise":"+3.11%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the continued strength of their product pipeline.","They emphasized a focus on innovation and long-term growth."],"summary":"Overall, management expressed confidence in their strategic direction. They acknowledged challenges but remained focused on delivering value."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 1.88%, possibly due to a lack of revenue data and no guidance for the future. Investors may be cautious as they await more information on the company's performance and outlook.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2018 earnings: EPS beat by 3.11%. Stock down 1.88%. Full breakdown."}}